Huang Lab Publishes Commentary on Driver Mutation Landscapes in Essential Thrombocythemia in Blood Science

SAN ANTONIO, Texas — The Huang Lab at the Mays Cancer Center at UT Health San Antonio announces a new commentary in Blood Science: "Driver mutation-defined molecular landscapes of essential thrombocythemia." The article appears in Volume 8, Issue 1, March 2026. Authors are Alejandra L. Lorenzen and Gang Huang.

The commentary examines a recent single-cell study of essential thrombocythemia, a myeloproliferative neoplasm marked by excessive platelet production and elevated clotting risk. That study profiled highly purified hematopoietic stem cells from treatment-naive patients, pairing single-cell sequencing with detection of the disease's driver mutations across JAK2, CALR, MPL, and triple-negative subtypes.

Lorenzen and Huang highlight three contributions. Each driver mutation imprints a distinct stem cell program, from lipid metabolic rewiring in MPL-mutated cells to mTOR-driven proliferation in CALR-mutated cells and inflammatory priming in JAK2-mutated cells. A specific CXCR4-positive stem cell subset is consistently depleted across all subtypes, and restoring it delayed disease onset in mice. Triple-negative disease carries a proliferative stem cell state that resembles mutated cells despite lacking the canonical drivers.

The authors weigh what these findings mean for tailored therapy while noting important limits, including questions about whether CXCR4 is a true functional driver and the difficulty of translating these strategies without harming normal blood formation. They argue that preserving balanced stem cell diversity may become a complementary therapeutic goal.

"This work reframes essential thrombocythemia around stem cell heterogeneity rather than clonal dominance alone," said Dr. Gang Huang, principal investigator. "Alejandra's analysis points toward mutation-informed strategies and the careful validation still needed before they reach patients."

DOI: https://doi.org/10.1097/BS9.0000000000000273

About the Huang Lab

The Huang Lab at UT Health San Antonio is a basic and translational cancer research group within the MD Anderson Mays Cancer Center at UT Health San Antonio. Our team integrates hematology and solid tumor biology with immunology and metabolism to uncover mechanisms and design interventions. We advance cell and biologic therapies, including CAR T-cell approaches for solid tumors. We also conduct research in trauma and military health. We move discoveries toward clinical impact through product development and collaborations with clinicians and industry. Education and mentorship are core to our mission. We train students, postdoctoral fellows, and early-career scientists in rigorous, multidisciplinary research. Together, we aim to deliver therapies and technologies that improve patient outcomes.